Stifel Initiates Coverage On Mirum Pharmaceuticals With Buy Rating, Announces Price Target of $48
Stifel Initiates Coverage On Mirum Pharmaceuticals With Buy Rating, Announces Price Target of $48
Stifel以買入評級啓動對Mirum Pharmicals的報道，宣佈目標股價爲48美元
Stifel analyst Dae Gon Ha initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and announces Price Target of $48.
Stifel分析師Dae Gon Ha以買入評級啓動了對Mirum Pharmicals（納斯達克股票代碼：MIRM）的報道，並宣佈目標股價爲48美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。